Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

The negative impact of antibiotics on outcomes in cancer patients treated with immunotherapy: a new independent prognostic factor?
Arielle Elkrief, Lisa Derosa, Guido Kroemer, et al.
Annals of Oncology (2019) Vol. 30, Iss. 10, pp. 1572-1579
Open Access | Times Cited: 193

Showing 1-25 of 193 citing articles:

Intestinal Akkermansia muciniphila predicts clinical response to PD-1 blockade in patients with advanced non-small-cell lung cancer
Lisa Derosa, Bertrand Routy, Andrew Maltez Thomas, et al.
Nature Medicine (2022) Vol. 28, Iss. 2, pp. 315-324
Open Access | Times Cited: 396
Microbiome and cancer
Nyssa Cullin, Camila Azevedo Antunes, Ravid Straussman, et al.
Cancer Cell (2021) Vol. 39, Iss. 10, pp. 1317-1341
Open Access | Times Cited: 358
The cancer-immunity cycle: Indication, genotype, and immunotype
Ira Mellman, Daniel S. Chen, Thomas Powles, et al.
Immunity (2023) Vol. 56, Iss. 10, pp. 2188-2205
Open Access | Times Cited: 345
Paradigms on Immunotherapy Combinations with Chemotherapy
Diego Salas‐Benito, José Luis Pérez‐Gracia, Mariano Ponz‐Sarvisé, et al.
Cancer Discovery (2021) Vol. 11, Iss. 6, pp. 1353-1367
Open Access | Times Cited: 309
Dietary tryptophan metabolite released by intratumoral Lactobacillus reuteri facilitates immune checkpoint inhibitor treatment
Mackenzie Bender, Alex McPherson, Catherine M. Phelps, et al.
Cell (2023) Vol. 186, Iss. 9, pp. 1846-1862.e26
Open Access | Times Cited: 299
Gut Bacteria Composition Drives Primary Resistance to Cancer Immunotherapy in Renal Cell Carcinoma Patients
Lisa Derosa, Bertrand Routy, Marine Fidelle, et al.
European Urology (2020) Vol. 78, Iss. 2, pp. 195-206
Open Access | Times Cited: 273
Moving towards personalized treatments of immune-related adverse events
Khashayar Esfahani, Arielle Elkrief, Cassandra Calabrese, et al.
Nature Reviews Clinical Oncology (2020) Vol. 17, Iss. 8, pp. 504-515
Closed Access | Times Cited: 247
The Gut Microbiome Associates with Immune Checkpoint Inhibition Outcomes in Patients with Advanced Non–Small Cell Lung Cancer
Taiki Hakozaki, Corentin Richard, Arielle Elkrief, et al.
Cancer Immunology Research (2020) Vol. 8, Iss. 10, pp. 1243-1250
Open Access | Times Cited: 224
The allergy mediator histamine confers resistance to immunotherapy in cancer patients via activation of the macrophage histamine receptor H1
Hongzhong Li, Yi Xiao, Qin Li, et al.
Cancer Cell (2021) Vol. 40, Iss. 1, pp. 36-52.e9
Open Access | Times Cited: 174
The yin and yang of co-inhibitory receptors: toward anti-tumor immunity without autoimmunity
Alexandra Schnell, Lloyd Bod, Asaf Madi, et al.
Cell Research (2020) Vol. 30, Iss. 4, pp. 285-299
Open Access | Times Cited: 173
CD8+ T cells in the cancer-immunity cycle
Josephine R. Giles, Anna-Maria Globig, Susan M. Kaech, et al.
Immunity (2023) Vol. 56, Iss. 10, pp. 2231-2253
Open Access | Times Cited: 158
Targeting the gut microbiota for cancer therapy
Miriam R. Fernandes, Poonam Aggarwal, Raquel Costa, et al.
Nature reviews. Cancer (2022) Vol. 22, Iss. 12, pp. 703-722
Closed Access | Times Cited: 149
Helicobacter pylori infection has a detrimental impact on the efficacy of cancer immunotherapies
P Oster, Laurie Vaillant, Erika Riva, et al.
Gut (2021) Vol. 71, Iss. 3, pp. 457-466
Open Access | Times Cited: 133
Intestinal microbiota influences clinical outcome and side effects of early breast cancer treatment
Safae Terrisse, Lisa Derosa, Valerio Iebba, et al.
Cell Death and Differentiation (2021) Vol. 28, Iss. 9, pp. 2778-2796
Open Access | Times Cited: 121
The gut microbiome: what the oncologist ought to know
Karla A. Lee, Marilan Luong, Heather Shaw, et al.
British Journal of Cancer (2021) Vol. 125, Iss. 9, pp. 1197-1209
Open Access | Times Cited: 107
γδ T cells: origin and fate, subsets, diseases and immunotherapy
Yi Hu, Qinglin Hu, Yongsheng Li, et al.
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 104
The role of the microbiome in ovarian cancer: mechanistic insights into oncobiosis and to bacterial metabolite signaling
Adrienn Sipos, Gyula Ujlaki, Edit Mikó, et al.
Molecular Medicine (2021) Vol. 27, Iss. 1
Open Access | Times Cited: 103
Fusobacterium nucleatum and cancer
Tamar Alon‐Maimon, Ofer Mandelboim, Gilad Bachrach
Periodontology 2000 (2022) Vol. 89, Iss. 1, pp. 166-180
Open Access | Times Cited: 99
A microbiota-modulated checkpoint directs immunosuppressive intestinal T cells into cancers
Marine Fidelle, Conrad Rauber, Carolina Alves Costa Silva, et al.
Science (2023) Vol. 380, Iss. 6649
Open Access | Times Cited: 91
Emerging roles of intratumor microbiota in cancer metastasis
Aikun Fu, Bingqing Yao, Tingting Dong, et al.
Trends in Cell Biology (2022) Vol. 33, Iss. 7, pp. 583-593
Closed Access | Times Cited: 70
Impact of Antibiotic Exposure Before Immune Checkpoint Inhibitor Treatment on Overall Survival in Older Adults With Cancer: A Population-Based Study
Lawson Eng, Rinku Sutradhar, Yue Niu, et al.
Journal of Clinical Oncology (2023) Vol. 41, Iss. 17, pp. 3122-3134
Closed Access | Times Cited: 49
Role of the Microbiome and Diet for Response to Cancer Checkpoint Immunotherapy: A Narrative Review of Clinical Trials
Lone Gamrath, Tina H. Pedersen, Mecker G. Möller, et al.
Current Oncology Reports (2025)
Open Access | Times Cited: 2
NSCLC Immunotherapy Efficacy and Antibiotic Use: A Systematic Review and Meta-Analysis
Lise Lurienne, Julie Cervesi, Lola Duhalde, et al.
Journal of Thoracic Oncology (2020) Vol. 15, Iss. 7, pp. 1147-1159
Open Access | Times Cited: 128
Indolepropionic Acid, a Metabolite of the Microbiome, Has Cytostatic Properties in Breast Cancer by Activating AHR and PXR Receptors and Inducing Oxidative Stress
Zsanett Sári, Edit Mikó, Tündé Kovàcs, et al.
Cancers (2020) Vol. 12, Iss. 9, pp. 2411-2411
Open Access | Times Cited: 104
Intestinal Microbiota: A Novel Target to Improve Anti-Tumor Treatment?
Romain Villéger, Amélie Lopès, Guillaume Carrier, et al.
International Journal of Molecular Sciences (2019) Vol. 20, Iss. 18, pp. 4584-4584
Open Access | Times Cited: 94
Page 1 - Next Page

Scroll to top